CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention
Table 2
Differences of clinical characteristics across genotypes.
Clinical factors
Total (%)
G119T
C432G
G/G
G/T&T/T
C/C
C/C&G/G
Age
0.461
1.174
≥66
86 (52)
53
33
68
18
Gender
1.050
0.269
Male
100 (61)
56
44
77
23
Tobacco use
0.041
0.016
Ever
67 (41)
39
28
51
16
Pathological type
1.783
0.619
6.476
0.091
AD
78 (48)
44
34
52
26
SQ
56 (34)
37
19
47
9
LA
19 (12)
10
9
16
3
Others
11 (7)
6
5
9
2
Differentiation
11.176
0.004
0.970
0.616
Well
50 (30)
39
11
Moderate
89 (57)
68
21
Poor
25 (15)
17
8
pTNM
T
9.448
0.024
5.657
0.130
T1
36 (22)
30
6
T2
60 (37)
49
11
T3
45 (27)
30
15
T4
23 (14)
15
8
N
1.287
0.732
1.320
0.724
N0
81 (49)
45
29
55
19
N1
31 (19)
8
15
24
9
N2
49 (30)
33
21
42
12
N3
3 (2)
1
2
3
0
M
0.076
0.102
M0
141 (86)
84
57
106
35
M1
23 (14)
13
10
18
5
Clinical stages
5.206
0.267
1.232
0.873
I
51 (31)
32
19
36
15
II
16 (10)
9
7
13
3
IIIa
59 (36)
38
21
45
14
IIIb
15 (9)
5
10
12
3
IV
23 (14)
13
10
18
5
subscript letter denotes a subset of the variate categories whose column proportions do not differ significantly from each other at the 0.05 level, as were calculated by Bonferroni method. value was adjusted by Fisher’s exact probability. AD, adenocarcinoma; SQ, squamous carcinoma; LA, large cell carcinoma; T, tumor staging; N, lymph node staging; M, metastasis staging.
